. Author manuscript; available in PMC: 2021 Sep 1.

Published in final edited form as: Am J Obstet Gynecol. 2020 Mar 12;223(3):419.e1–419.e16. doi: 10.1016/j.ajog.2020.03.004

Table 3.

Subgroup analysis. Incidence of Superimposed Preeclampsia without and with Severe Features

	Pre ACOG N=254	Post ACOG N=203	P-value
Incidence of Superimposed Preeclampsia without Severe Features
ONLY CHTN^a	53/170 (31.2)	34/119 (28.6)	0.70
CHTN with Anti-hypertensive Meds	46/117 (39.3)	22/61 (36.1)	0.75
CHTN and History of Preeclampsia	25/55 (45.4)	28/61 (45.9)	1.0
CHTN and Pre-gestational Diabetes	13/35 (37.1)	12/29 (41.4)	0.8
Incidence of Superimposed Preeclampsia with Severe Features
Only CHTN^a	34/170 (20.0)	31/119 (26.0)	0.25
CHTN with Antihypertensive Meds	35/117 (29.9)	19/61 (31.1)	0.87
CHTN and History of Preeclampsia	15/55 (27.3)	25/61 (40.9)	0.17
CHTN and Pre-gestational Diabetes	8/35 (22.8)	9/29 (31.0)	0.57

Values reported as n (%).

ACOG: American College of Obstetricians and Gynecologists

CHTN: Chronic hypertension

Only CHTN group (women with history of preeclampsia, or medical conditions as pregestational diabetes, renal disease, vascular disease, antiphospholipid syndrome, autoimmune disorder, sickle cell disease were excluded)